[1] Sarin SK,Kumar A,Angus PW,et al. Diagnosis and management of acute variceal bleeding:Asian Pacific Association for Study of the Liver recommendations. Hepatol Int,2011,5（2）:607-624.
[2] 中华医学会肝病学分会、消化病学分会、消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南. 中华内科杂志,2016,55（1）:57-72.
[3] Hadduck TA,McWilliams JP. Partial splenic artery embolization in cirrhotic patients. World J Radiol,2014,6（5）:160-168.
[4] Alwmark A,Bengmark S,Gullstrand P,et al. Evaluation of splenic embolization in patients with portal hypertension and hypersplenism. Ann Surg,1982,196（5）:518-524.
[5] 刘学键,李恩山,马幼平,等. 联合介入栓塞治疗门静脉高压症的临床研究. 中国普通外科杂志,2008,18（1）:70-74.
[6] Gong WD,Xue K,Chu YK,et al. Percutaneous transhepatic embolization of gastroesophageal varices combined with partial splenic embolization for the treatment of variceal bleeding and hypersplenism. Int J Clin Exp Med,2015,8（10）:19642-19661.
[7] Ohmoto K,Yamamoto S. Prevention of variceal recurrence,bleeding,and death in cirrhosis patients with hypersplenism,especially those with severe thrombocytopenia. Hepatogastroenterology,2003,50（54）:1766-1769.
[8] Tian X,Shi Y,Hu J,et al. Percutaneous transhepatic variceal embolization with cyanoacrylate vs. transjugular intrahepatic portal systematic shunt for esophageal variceal bleeding. Hepatol Int,2013,7（2）:636-644.
[9] Duan X,Zhang K,Han X,et al. Comparison of percutaneous transhepatic variceal embolization（PTVE） followed by partial splenic embolization versus PTVE alone for the treatment of acute esophagogastric variceal massive hemorrhage. J Vasc Interv Radiol,2014,25（12）:1858-1865.
[10] 周光文,杨连粤. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识（2015）. 中国实用外科杂志,2015,35（10）:1086-1090.
[11] Kapoor A,Dharel N,Sanyal AJ. Endoscopic diagnosis and therapy in gastroesophageal variceal bleeding. Gastrointest Endosc Clin N Am,2015,25（3）:491-507.
[12] Triantafyllou M,Stanley AJ. Update on gastric varices. World J Gastrointest Endosc,2014,6（5）:168-175.
[13] Kwak HS1,Han YM. Percutaneous transportal sclerotherapy with N-butyl-2-cyanoacrylate for gastric varices:technique and clinical efficacy. Korean J Radiol,2008,9（6）:526-533.
[14] Wang J,Tian XG,Li Y,et al. Comparison of modified percutaneous transhepatic variceal embolization and endoscopic cyanoacrylate injection for gastric variceal rebleeding. World J Gastroenterol,2013,19（5）:706-714.
[15] Kanagawa H,Mima S,Kouyama H,et al. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol,1996,11（1）:51-58.
[16] Hashizume M,Tsugawa K,Migo S,et al. Eradication of large gastric varices by sclerotherapy combined with percutaneous transhepatic obliteration. Hepatogastroenterology,1997,44（13）:221-226.
[17] Violi F,Ferro D,Basili S,et al. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. Hepatology,1993,17（1）:78-83.
[18] Parikh S,Shah R,Kapoor P. Portal vein thrombosis. Am J Med,2010,123（2）:111-119.
[19] Molmenti EP,Roodhouse TW,Molmenti H,et al. Thrombendvenectomy for organized portal vein thrombosis at the time of liver transplantation. Ann Surg,2002,235（2）:292-296.
[20] Amitrano L,Guardascione MA,Brancaccio V,et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol,2004,40:736-741.
[21] Chawla YK,Bodh V. Portal vein thrombosis. J Clin Exp Hepatol,2015,5（1）:22-40.
[22] 吴刚,刘永锋,陈旭春. 肝移植门静脉血栓形成的预防和治疗. 中华器官移植杂志,2006,27（10）:612-624.
[23] 高坌,王剑锋,魏宝杰,等.肝移植术后门静脉狭窄的血管内介入治疗. 中华器官移植杂志,2012,33（5）:291-294.
[24] Cheng YF,Ou HY,Tsang LL,et al. Vascular stents in the management of portal venous complications in living donor liver transplantation. Am J Transplant,2010,10（5）:1276-1283.
[25] Habib A,Desai K,Hickey R,et al. Portal vein recanalization- transjugular intrahepatic portosystemic shunt using the transsplenic approach to achieve transplant candidacy in patients with chronic portal vein thrombosis. J Vasc Interv Radiol,2015,26（4）:499-506.
[26] 韩国宏,孟祥杰,殷占新,等. 经颈内静脉肝内门腔分流术及联合经皮肝/脾穿刺途径治疗门静脉血栓和（或）海绵样变性. 中华医学杂志,2009,89（22）:1549-1552.
[27] Holster IL,Tjwa ET,Moelker A,et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy+ β-blocker for prevention of variceal rebleeding. Hepatology,2016,63（2）:581-589.
[28] Lauermann J,Potthoff A,Mc Cavert M,et al. Comparison of technical and clinical outcome of transjugular portosystemic shunt placement between a bare metal stent and a PTFE-stentgraft device. Cardiovasc Intervent Radiol,2016,39（4）:547-556.
[29] Boyer TD,Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt （TIPS） in the management of portal hypertension:update 2009. Hepatology,2010,51（1）:306.
[30] 中华医学会消化病学分会,中华医学会肝病学分会,中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治共识（2008,杭州）. 中华消化杂志,2008,28（8）:551-558.
[31] Grunwald D,Tapper EB,Jiang ZG,et al. A standardized assessment of functional disability predicts 1-year mortality in patients undergoing transjugular intrahepatic portosystemic shunt for refractory ascites. J Clin Gastroenterol,2016,50（1）:75-79.
[32] Mancuso A. An update on management of Budd-Chiari syndrome. Ann Hepatol,2014,13（3）:323-326.
[33] Raja K,Jacob M,Asthana S. Portal vein thrombosis in cirrhosis. J Clin Exp Hepatol,2014,4（4）:320-331.
[34] García-Pagán JC,Caca K,Bureau C,et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med,2010,362（25）:2370-2379.
[35] De Franchis R, Baveno V Faculty. Revising consensus in portal hypertension:report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol,2010,53（4）:762-768.
[36] De Franchis R,Baveno VI Faculty. Expanding consensus in portal hypertension：Report of the Baveno VI Consensus Workshop：Stratifying risk and individualizing care for portal hypertension. J Hepatol,2015,63（3）:743-752.
[37] Tripathi D,Stanley AJ,Hayes PC,et al. Clinical Services and Standards Committee of the British Society of Gastroenterology.U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut,2015,64（11）:1680-1704.
[38] Garcia-Pagán JC,Di Pascoli M,Caca K,et al. Use of early-TIPS for high-risk variceal bleeding:results of a post-RCT surveillance study. J Hepatol,2013,58（1）:45-50.
[39] Charon JP,Alaeddin FH,Pimpalwar SA,et al. Results of a retrospective multicenter trial of the Viatorr expanded polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt creation. Vasc Interv Radiol,2004,15（11）:1219-1230.
[40] Hausegger KA,Karnel F,Georgieva B,et al. Transjugular intrahepatic portosystemic shunt creation with the Viatorr expanded polytetrafluoroethylene-covered stent-graft. J Vasc Interv Radiol, 2004,15（3）:239-248.
[41] Sauerbruch T,Mengel M,Dollinger M,et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology,2015,149（3）:660-668.
[42] Habib A,Desai K,Hickey R,et al. Portal vein recanalization-transjugularintrahepatic portosystemic shunt using the transsplenic approach to achieve transplant candidacy in patients with chronic portal vein thrombosis. J Vasc Interv Radiol,2015,26（4）:499-506.
[43] Bissonnette J,Garcia-Pagán JC,Albillos A,et al. Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. Hepatology,2016,Mar 17. doi:10.1002/hep.28547. [Epub ahead of print] |
